Study Overview
Bring It Up
Research shows that more than half of patients will participate in a clinical trial if their healthcare provider discusses it with them.1 Learn about and discuss RISE UP with your patients with sickle cell disease.
Rise up Clinical Study Design2
PHASE 2
PHASE 3
BID=twice daily.
Participants will be enrolled in either phase 2 or phase 3 of RISE UP.
Once enrolled, participants cannot reenroll in a different phase.2
Key Inclusion Criteria2
- Age 16 years or older, with a documented diagnosis of sickle cell disease (HbSS, HbSC, HbS/β0 thalassemia, HbS/β+ thalassemia, or other sickle cell syndrome variants)
- At least 2 and no more than 10 sickle cell pain crises in the past 12 months prior to informed consent
- Defined as acute episodes of pain, acute chest syndrome, priapism, hepatic or splenic sequestration
- If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before randomization
Key Exclusion Criteria2
- Pregnant or breastfeeding
- Receiving regularly scheduled transfusions
- Hepatobiliary disorders, significant liver disease, gallbladder disease, or severe kidney disease
- Prior exposure to gene therapy or prior bone marrow or stem cell transplantation
- Currently receiving voxelotor, crizanlizumab, or L-glutamine
- Currently receiving treatment with hematopoietic-stimulating agents
- Taking strong CYP3A4/5 inhibitors or strong inducers of CYP3A4
Get ready for the next phase of rise up
Learn more about RISE UP, including full enrollment details, all study objectives, and key inclusion and exclusion details. Then talk to your eligible patients about the study.
Call Agios Pharmaceuticals Medical Affairs at 1-833-228-8474, Mon-Fri, 9 am to 7 pm ET, or email medinfo@agios.com.
References:
1. Research!America. National public opinion poll. https://www.researchamerica.org/sites/default/files/uploads/clinicaltrialsminorities.pdf. July 2013. Accessed March 3, 2022.
2. Data on file. Agios Pharmaceuticals, Inc.